This mouse anti-EGFR monoclonal antibody is specific to human EGFR. EGFR monoclonal antibody recognizes the expressed product of the EGFR gene. EGFR over-expression in tumors indicates poorprognosis. EGFR over-expression is observed in tumors of the head and neck, brain, bladder, stomach, breast, lung, endometrium, cervix, vulva, ovary, esophagus, and stomach, and in squamous cell carcinoma. Validated applications for EGFR monoclonal antibody are immunoprecipitation, immunohistochemistry, and Western blotting.

Antibody Attributes:

• Applications: Validated applications for EGFR monoclonal antibody are immunoprecipitation, immunohistochemistry, and Western blotting.
• Host Species and Isotype: The host species and isotype of the EGFR monoclonal antibody is mouse IgG1 and mouse IgG2a.
• Clone ID of Monoclonal Antibody (mAb): The EGFR monoclonal antibody clone ID is R19/48MIX.
• Reactivity: EGFR monoclonal antibody detects human EGFR.
• Product Size: EGFR monoclonal antibody is available in a 100 µg pack size.

This mixture of four monoclonal antibodies binds to proteins with Mw = 170 kDa and 145 kDa, corresponding to the intact and vIII-variant of EGFR. The epitopes for these antibodies map to the extracellular and cytoplasmic domains of EGFR. EGFR is the prototype member of the type 1 receptor tyrosine kinases. EGFR is encoded by the cellular oncogene c-erbB-1. EGFR has an extracellular ligand binding domain, a single transmembrane region, and cytoplasmic domain which is composed of a tyrosine kinase domain and a carboxyterminal domain. The carboxyterminal domain contains at least four tyrosine autophosphorylation sites. EGFR over-expression in tumors indicates poor prognosis. EGFR over-expression is observed in tumors of the head and neck, brain, bladder, stomach, breast, lung, endometrium, cervix, vulva, ovary, esophagus, and stomach, and in squamous cell carcinoma.